Former Agent Suing DEA over Positive THC Test That Resulted in Termination
The agent claimed he frequently used CBD for pain management, which contributed to the levels of THC found in a urinalysis.
On May 19, 2023, former DEA Special Agent Anthony Armour filed a lawsuit against the Drug Enforcement Administration (DEA) claiming wrongful termination over a positive THC test result (1). Armour, a 15-year DEA veteran, had worked fighting the opioid epidemic for several years when a random drug test in 2019 revealed over-the-limit levels of THC, causing his termination with a charge of drug possession or use (1).
Armour explained that after over-the-counter medications had failed to help mange his pain caused injuries from his football and police officer careers, he turned to hemp-based cannabidiol (CBD), since it had recently been legalized through the Farm Bill in 2018 (2). At that time, the lawsuit claimed, the DEA did not have regulations or warnings relating to employee use of CBD in relation to drug screenings, and only established these regulations during the investigation of Armour (1,2).
The lawsuit stated that the ruling from the DEA Board of Conduct should be overturned for several reasons including a lack of evidence establishing Armour’s CBD use as illegal or that he knowingly and intentionally purchased and used a controlled substance (2). “Everyone, including the DEA, agrees that the urinalysis test cannot distinguish between THC consumed from legal hemp versus marijuana,” the lawsuit noted (2).
In its conclusion, the lawsuit argued that Armour should be reinstated as Special Agent with back pay, benefits, and seniority (2). The lawsuit is now before the US court of Appeals for the Federal Circuit (2).
For more information on regulatory oversight in the CBD market, read our blog on the topic.
References
- HempToday® Opioid-fighting agent fired over CBD use hits DEA with lawsuit https://hemptoday.net/opioid-fighting-agent-fired-over-cbd-use-fights-back-with-lawsuit-vs-dea/ (accessed May 31, 2023).
- Jaeger, K. DEA is being sued by a former agent who was “wrongfully terminated” over CBD use https://www.marijuanamoment.net/dea-is-being-sued-by-a-former-agent-who-was-wrongfully-terminated-over-cbd-use/ (accessed May 31, 2023).
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part I
December 16th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Work Smarter, Not Harder: How ASTM Standards for Cannabinoids Improve Your Operations
December 3rd 2024ASTM Standards D8557-24 and D8556-24, provide unified guidelines for GMP (Good Manufacturing Practices) and QMS (Quality Management Systems) in cannabis operations. These standards enhance compliance, product safety, and operational consistency across the industry for the benefit of operators, consumers, and other stakeholders in the industry.
